Bengaluru, India: September 19, 2016
Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, announced today that Mr Suresh Subramanian has been appointed as Senior Vice President & Head of the Company's Branded Formulations (India) business.
Suresh has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline, Novartis, AstraZeneca and Pfizer. Over the years, he has played multiple leadership roles in Business Development, Marketing, Sales and Strategy. He has a rich experience of multiple product launches, business optimization, cost control, talent development and performance management.
Suresh has managed a wide portfolio spanning diverse therapy areas such as Neurosciences, Respiratory, Cardiology, Oncology, Critical Care, Gastro-Intestinal, Ophthalmology, Pain & Inflammation and Women's Health in the Indian market. He has also played a critical role in mapping the pharma opportunity in India as part of the Steering Committee for McKinsey's India Pharma 2020 report.
Ms Kiran Mazumdar-Shaw, CMD, Biocon, said: "We are extremely delighted to have Suresh Subramanian lead our Branded Formulations business in India. Suresh has deep expertise in diverse therapy areas including Oncology, Cardiology and Critical Care and has a proven track record of delivering robust business growth. We are sure, under his leadership, our Branded Formulations business will evolve further and become a strong value builder for Biocon."
Biocon's Branded Formulations (India) business is a biologics-led, specialty pharma business focused on the chronic therapy areas of diabetes, cancer and autoimmune conditions. Many of its key brands are leaders in their respective categories. ALZUMAb™, a novel biologic developed by Biocon, is the world's first anti-CD6 monoclonal antibody introduced in India for Psoriasis. INSUGEN® is the largest Indian Insulins brand, while BASALOG® is a leading Indian Insulin Glargine brand. CANMAb™ an affordable Trastuzumab for metastatic breast cancer has benefitted several thousand patients in India.
Suresh Subramanian is a Physics graduate and has a Masters in Marketing Management from Mumbai University.
About Biocon Ltd:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog. Visit: archive.biocon.com
For More Information Contact:
Media Relations
Seema Ahuja
VP & Global Head of Communications
Phone: +91-80-2808-2222, M:+91-9972317792
Email: seema.ahuja@biocon.com
Rumman Ahmed
Senior Manager, Corporate Communications
Phone: +91 80 6775 2223; +91-9845104173
Email: rumman.ahmed@biocon.com
Investor Relations
Saurabh Paliwal
Head, Investor Relations
Phone: +91 80 6775 2040; +91 9538380801
Email: saurabh.paliwal@biocon.com
|
